Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells

Our results show that using an EBV-LCL feeder cell line, large numbers of pure populations of highly activated NK cells can be expanded ex vivo under GMP conditions. With the exception of thyroiditis and constitutional symptoms related to IL-2 therapy, infusions of up to 1 x 10(8) cells/kg of ex viv...

Descripción completa

Detalles Bibliográficos
Autores principales: Lundqvist, Andreas, Berg, Maria, Smith, Aleah, Childs, Richard W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2011
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3133963/
https://www.ncbi.nlm.nih.gov/pubmed/21750690
_version_ 1782207937088847872
author Lundqvist, Andreas
Berg, Maria
Smith, Aleah
Childs, Richard W.
author_facet Lundqvist, Andreas
Berg, Maria
Smith, Aleah
Childs, Richard W.
author_sort Lundqvist, Andreas
collection PubMed
description Our results show that using an EBV-LCL feeder cell line, large numbers of pure populations of highly activated NK cells can be expanded ex vivo under GMP conditions. With the exception of thyroiditis and constitutional symptoms related to IL-2 therapy, infusions of up to 1 x 10(8) cells/kg of ex vivo expanded NK have been well tolerated and have provided preliminary clinical evidence for mediating anti-tumor immunity in patients with advanced cancer.
format Online
Article
Text
id pubmed-3133963
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-31339632011-07-12 Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells Lundqvist, Andreas Berg, Maria Smith, Aleah Childs, Richard W. J Cancer Short Report Our results show that using an EBV-LCL feeder cell line, large numbers of pure populations of highly activated NK cells can be expanded ex vivo under GMP conditions. With the exception of thyroiditis and constitutional symptoms related to IL-2 therapy, infusions of up to 1 x 10(8) cells/kg of ex vivo expanded NK have been well tolerated and have provided preliminary clinical evidence for mediating anti-tumor immunity in patients with advanced cancer. Ivyspring International Publisher 2011-07-01 /pmc/articles/PMC3133963/ /pubmed/21750690 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Short Report
Lundqvist, Andreas
Berg, Maria
Smith, Aleah
Childs, Richard W.
Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
title Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
title_full Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
title_fullStr Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
title_full_unstemmed Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
title_short Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
title_sort bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3133963/
https://www.ncbi.nlm.nih.gov/pubmed/21750690
work_keys_str_mv AT lundqvistandreas bortezomibtreatmenttopotentiatetheantitumorimmunityofexvivoexpandedadoptivelyinfusedautologousnaturalkillercells
AT bergmaria bortezomibtreatmenttopotentiatetheantitumorimmunityofexvivoexpandedadoptivelyinfusedautologousnaturalkillercells
AT smithaleah bortezomibtreatmenttopotentiatetheantitumorimmunityofexvivoexpandedadoptivelyinfusedautologousnaturalkillercells
AT childsrichardw bortezomibtreatmenttopotentiatetheantitumorimmunityofexvivoexpandedadoptivelyinfusedautologousnaturalkillercells

Ejemplares similares